Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cav-1 RNAi
- Development stage
- Preclinical
- Lead developer
- University of Virginia
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Cav-1 RNAi refers to RNA interference (RNAi) molecules, such as small interfering RNAs (siRNAs) or short hairpin RNAs (shRNAs), designed to silence the expression of the Caveolin-1 (Cav-1) gene. Caveolin-1 is a primary component of caveolae plasma membrane invaginations and plays a significant role in signal transduction and cellular trafficking. In the context of oncology, particularly bladder cancer, Cav-1 is often overexpressed and associated with aggressive tumor behavior and metastasis. Research indicates that depleting Cav-1 via RNAi can lead to reduced cell migration and decreased metastatic potential by modulating Rho GTPase activity (specifically RhoA and RhoC) and interacting with Src kinase pathways.
- Other names
- Caveolin-1 RNA interferenceCaveolin1 RNA interferenceCaveolin 1 RNA interferenceCav-1 siRNACav1 siRNACav 1 siRNACav-1 shRNACav1 shRNACav 1 shRNA
02
Targets
CAV1 (Caveolin-1)
Beyond the preview
Go deeper on Cav-1 RNAi.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cav-1 RNAi.